Toviaz

Pfizer has launched Toviaz (fesoterodine), a once-daily treatment for the symptoms of overactive bladder including urinary frequency, urgency or urgency incontinence.

Toviaz
Toviaz

PHARMACOLOGY
Fesoterodine is a competitive, specific muscarinic receptor antagonist. It is rapidly and extensively hydrolysed by non-specific plasma esterases to the 5-hydroxymethyl derivative, its primary active metabolite.

CLINICAL STUDIES
The efficacy of fesoterodine has been assessed in two phase III 12-week trials1,2 in patients with overactive bladder syndrome.

Patients were randomised to placebo, 4mg fesoterodine or 8mg fesoterodine once daily for 12 weeks. The primary efficacy end point was the change in the number of micturitions per 24 hours. Co-primary end points were the change in the number of urgency urinary incontinence (UUI)episodes per 24 hours and the treatment response.

The trials showed statistically significant and clinically relevant improvements in primary and co-primary end points in patients taking 4mg fesoterodine and 8mg fesoterodine compared to placebo.

View Toviaz drug record

References:
1. Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007: 52; 1204–12.
2. Nitti V, Dmochowski R, Sand P et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007: 178; 2488–94.

Further information: Pfizer


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases